|
US7365093B2
(en)
*
|
1994-08-19 |
2008-04-29 |
Abbott Laboratories |
Endothelin antagonists
|
|
GB0004297D0
(en)
*
|
2000-02-23 |
2000-04-12 |
Ucb Sa |
2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
|
|
US6686477B2
(en)
*
|
2000-09-29 |
2004-02-03 |
Eastman Chemical Company |
Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
|
|
WO2002067931A1
(en)
*
|
2001-02-23 |
2002-09-06 |
Johns Hopkins University |
Treatment of tics, tremors and related disorders
|
|
EP1419144B1
(en)
|
2001-08-10 |
2008-10-08 |
UCB Pharma S.A. |
Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
|
|
CA2461961A1
(en)
*
|
2001-10-08 |
2003-04-17 |
Ucb, S.A. |
Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
|
|
BR0213660A
(pt)
|
2001-10-16 |
2004-08-24 |
Memory Pharm Corp |
Composto, composição farmacêutica e método para tratar pacientes
|
|
AU2003242538A1
(en)
*
|
2002-05-14 |
2003-11-11 |
Ucb, S.A. |
Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
|
|
DE602004023051D1
(de)
*
|
2003-01-13 |
2009-10-22 |
Ucb Pharma Sa |
Hydrierungskatalysatoren
|
|
WO2004069796A2
(en)
*
|
2003-02-03 |
2004-08-19 |
Teva Pharmaceutical Industries Ltd. |
Process for producing levetiracetam
|
|
ES2214147B1
(es)
|
2003-02-28 |
2005-10-01 |
Farma-Lepori S.A. |
Procedimiento de obtencion de un agente antiepileptico.
|
|
WO2004083180A1
(en)
*
|
2003-03-18 |
2004-09-30 |
Hetero Drugs Limited |
Novel crystalline forms of levetiracetam
|
|
RU2232578C1
(ru)
*
|
2003-04-10 |
2004-07-20 |
Ахапкина Валентина Ивановна |
Вещество, обладающее антидепрессивной активностью
|
|
KR20060039392A
(ko)
|
2003-04-16 |
2006-05-08 |
메모리 파마슈티칼스 코포레이션 |
포스포디에스테라제 4 억제제
|
|
US7034051B2
(en)
*
|
2003-08-28 |
2006-04-25 |
Adolor Corporation |
Fused bicyclic carboxamide derivatives and methods of their use
|
|
EP1663968A1
(en)
*
|
2003-09-05 |
2006-06-07 |
Ranbaxy Laboratories Limited |
Process for the preparation of pure levetiracetam
|
|
ES2390455T3
(es)
*
|
2003-09-24 |
2012-11-13 |
Ucb Pharma, S.A. |
Procedimiento para la preparación de derivados de 2-oxo-1-pirrolidina
|
|
JP2007513105A
(ja)
*
|
2003-12-02 |
2007-05-24 |
ユ セ ベ ソシエテ アノニム |
イミダゾール誘導体、その製法及び使用
|
|
WO2005121082A1
(en)
*
|
2004-06-11 |
2005-12-22 |
Ucb, S.A. |
Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
|
|
RS51210B
(sr)
*
|
2004-06-21 |
2010-12-31 |
Warner-Lambert Company Llc. |
Dobijanje pregaballina i srodnih jedinjenja
|
|
US7427601B2
(en)
*
|
2004-06-24 |
2008-09-23 |
Schwarz Pharma Ag |
Method for treating tremor
|
|
US7585882B2
(en)
|
2004-10-20 |
2009-09-08 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors
|
|
CA2488325C
(en)
*
|
2004-11-22 |
2010-08-24 |
Apotex Pharmachem Inc. |
Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
|
|
EP2308870A3
(en)
|
2005-06-01 |
2011-10-19 |
UCB Pharma S.A. |
2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses
|
|
EP1731149A1
(en)
*
|
2005-06-08 |
2006-12-13 |
Ucb S.A. |
Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
|
|
ES2530398T3
(es)
*
|
2005-09-15 |
2015-03-02 |
Ucb Pharma Sa |
Pirrolidin-2-onas 4-sustituidas y su uso
|
|
JP2007153755A
(ja)
*
|
2005-12-01 |
2007-06-21 |
Gifu Univ |
プロリン類縁体
|
|
EP1993998B1
(en)
*
|
2005-12-07 |
2013-08-21 |
UCB Pharma, S.A. |
3-carboxy- 2-oxo-1 -pyrrolidine derivatives and their uses
|
|
US8338621B2
(en)
|
2005-12-21 |
2012-12-25 |
Ucb S.A. |
Process for the preparation of 2-oxo-1-pyrrolidine derivatives
|
|
LV13630B
(en)
*
|
2006-03-16 |
2007-12-20 |
Olainfarm As |
Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
|
|
EP2041084B1
(en)
*
|
2006-06-08 |
2013-11-06 |
UCB Pharma, S.A. |
Co-crystals of pyrrolidinones
|
|
ES2531118T5
(es)
|
2006-06-15 |
2022-06-14 |
Ucb Pharma Gmbh |
Composición farmacéutica que comprende lacosamida y levetiracetamo para uso en el tratamiento de la epilepsia
|
|
EP2051696A2
(en)
*
|
2006-08-18 |
2009-04-29 |
Morton Grove Pharmaceuticals, Inc. |
Stable liquid levetiracetam compositions and methods
|
|
SI2076508T1
(sl)
*
|
2006-10-18 |
2011-04-29 |
Pfizer Prod Inc |
Spojine biaril eter sečnine
|
|
US8828665B2
(en)
|
2007-02-16 |
2014-09-09 |
Ark Diagnostics, Inc. |
Compounds and methods for use in detecting gabapentin
|
|
WO2008132142A2
(en)
*
|
2007-04-27 |
2008-11-06 |
Ucb Pharma S.A. |
New heterocyclic derivatives useful for the treatment of cns disorders
|
|
US20090082422A1
(en)
*
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched levetiracetam
|
|
PT2273975E
(pt)
*
|
2008-03-03 |
2014-07-17 |
Ucb Pharma Sa |
Processos de preparação e utilizações terapêuticas de soluções farmacêuticas
|
|
US7741327B2
(en)
*
|
2008-04-16 |
2010-06-22 |
Hoffmann-La Roche Inc. |
Pyrrolidinone glucokinase activators
|
|
US20110212944A1
(en)
*
|
2008-07-01 |
2011-09-01 |
Julie Liu |
2-oxo-1-pyrrolidine derivatives
|
|
EP2147911A1
(en)
|
2008-07-24 |
2010-01-27 |
ZaCh System S.p.A. |
Process for the preparation of levetiracetam
|
|
JP4644881B2
(ja)
*
|
2008-09-19 |
2011-03-09 |
高砂香料工業株式会社 |
ルテニウム錯体の製造方法
|
|
DK2346500T3
(en)
|
2008-10-16 |
2017-07-17 |
Univ Johns Hopkins |
Methods and compositions for improving cognitive function
|
|
WO2010048423A1
(en)
|
2008-10-24 |
2010-04-29 |
Ark Diagnostics, Inc. |
Levetiracetam immunoassays
|
|
JP5753785B2
(ja)
*
|
2008-11-07 |
2015-07-22 |
ノバベイ・ファーマシューティカルズ・インコーポレイテッドＮｏｖａｂａｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
抗菌オキサゾリジノン、ヒダントインおよびイミダゾリジノン組成物
|
|
PT2358361T
(pt)
*
|
2008-11-18 |
2016-11-18 |
Ucb Biopharma Sprl |
Formulações de libertação prolongada compreendendo um derivado de 2-oxo-1-pirrolidina
|
|
CN104208714A
(zh)
*
|
2008-11-18 |
2014-12-17 |
Ucb医药有限公司 |
含有2-氧代-1-吡咯烷衍生物的延长释放制剂
|
|
FR2939311A1
(fr)
*
|
2008-12-08 |
2010-06-11 |
Oreal |
Utilisation d'un derive diester de pyrrolidinone 4-carboxy comme solvant dans les compositions cosmetiques ; compositions cosmetiques les contenant
|
|
US8563036B2
(en)
|
2009-02-09 |
2013-10-22 |
Ucb Pharma, S.A. |
Pharmaceutical compositions comprising Brivaracetam
|
|
US8846411B2
(en)
*
|
2009-06-11 |
2014-09-30 |
Microgenics Corporation |
Derivatives, reagents, and immunoassay for detecting levetiracetam
|
|
US20120171125A1
(en)
|
2009-08-07 |
2012-07-05 |
Ucb Pharma, S.A. |
Methods for Enhancing the Cognitive Function
|
|
US7939676B2
(en)
|
2009-09-17 |
2011-05-10 |
Zach System S.P.A. |
Process for the preparation of levetiracetam
|
|
US8487591B1
(en)
|
2009-12-31 |
2013-07-16 |
Cirrus Logic, Inc. |
Power control system with power drop out immunity and uncompromised startup time
|
|
PL389364A1
(pl)
|
2009-10-23 |
2011-04-26 |
Uniwersytet Jagielloński |
Nowe zastosowanie pochodnych 2-pirolidonu
|
|
BR112012009310B8
(pt)
|
2009-10-23 |
2021-05-25 |
Ucb Biopharma Sprl |
composto derivados de 2-oxo-1-pirrolidinil imidazotiadiazol, uso dos mesmos e composição farmacêutica compreendendo os mesmos
|
|
EP2533645B1
(en)
|
2010-02-09 |
2016-07-27 |
The Johns Hopkins University |
Methods and compositions for improving cognitive function
|
|
FR2961098A1
(fr)
|
2010-06-09 |
2011-12-16 |
Oreal |
Composition comprenant au moins une 2-pyrrolidone fonctionnalisee en position 4 par un acide carboxylique ou amide, et au moins un colorant direct ou un pigment pour la teinture des fibres keratiniques
|
|
FR2961101B1
(fr)
|
2010-06-09 |
2013-01-25 |
Oreal |
Composition comprenant au moins une 2-pyrrolidone fonctionnalisee par un radical ester ou amide, et au moins un pigment ou un colorant direct pour la teinture des matieres keratiniques
|
|
FR2961099B1
(fr)
|
2010-06-09 |
2012-06-15 |
Oreal |
Derives de 2-pyrrolidone fonctionnalisee par un radical ester, acide ou amide, la composition cosmetique les comprenant et leur utilisation pour le conditionnement des matieres keratiniques
|
|
US8466297B2
(en)
|
2010-11-01 |
2013-06-18 |
Milan Soukup |
Manufacturing process for (S)-Pregabalin
|
|
JP5916746B2
(ja)
|
2010-11-15 |
2016-05-11 |
エージンバイオ， インコーポレイテッド |
認知障害を処置するためのピリダジン誘導体、組成物、および方法
|
|
AU2012214303A1
(en)
*
|
2011-02-09 |
2013-09-12 |
The Johns Hopkins University |
Methods and compositions for improving cognitive function
|
|
EP2699581B1
(en)
|
2011-04-18 |
2015-11-25 |
UCB Biopharma SPRL |
2-oxo-1-imidazolidinyl imidazothiadiazole derivatives
|
|
CN107353316B
(zh)
|
2011-09-30 |
2020-08-18 |
塔夫斯大学 |
用于治疗神经变性疾病的尿苷二磷酸衍生物、组合物和方法
|
|
EP2797879B1
(en)
*
|
2011-12-27 |
2018-12-26 |
Bio-Pharm Solutions Co., Ltd. |
Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain
|
|
TW201408294A
(zh)
*
|
2012-07-05 |
2014-03-01 |
Merz Pharma Gmbh & Co Kgaa |
(r)-苯基披喇瑟盪於治療帕金森氏症之用除
|
|
TW201408293A
(zh)
*
|
2012-07-05 |
2014-03-01 |
Merz Pharma Gmbh & Co Kgaa |
(r)-苯基披喇瑟盪於治療疾病相關疲勞之用途
|
|
WO2014052896A1
(en)
|
2012-09-28 |
2014-04-03 |
Tufts University |
Uridine diphosphate derivatives, prodrugs, compositions and uses thereof
|
|
JP6440625B2
(ja)
|
2012-11-14 |
2018-12-19 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
精神分裂病を処置するための方法および組成物
|
|
US9738915B2
(en)
|
2012-12-07 |
2017-08-22 |
Merck Sharp & Dohme Corp. |
Biocatalytic transamination process
|
|
WO2014087367A2
(en)
*
|
2012-12-09 |
2014-06-12 |
Mahesh Kandula |
Compositions and methods for the treatment of neurological diseases and its associated complications
|
|
US9970929B2
(en)
|
2013-01-18 |
2018-05-15 |
Ark Diagnostics, Inc. |
Voriconazole immunoassays
|
|
EP2956444B1
(en)
|
2013-02-13 |
2018-05-30 |
ARK Diagnostics, Inc. |
Posaconazole immunoassays
|
|
AR095442A1
(es)
|
2013-03-13 |
2015-10-14 |
Univ Tufts |
Derivados de nucleósido de uridina, composiciones y métodos de uso
|
|
HUE039871T2
(hu)
|
2013-03-13 |
2019-02-28 |
Univ Tufts |
Uridin nukleozid származékok, kompozíciók és alkalmazási eljárások
|
|
EP2968237A4
(en)
|
2013-03-15 |
2016-08-31 |
Univ Johns Hopkins |
METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
|
|
EP2968220B1
(en)
|
2013-03-15 |
2021-05-05 |
Agenebio, Inc. |
Methods and compositions for improving cognitive function
|
|
CN103342672B
(zh)
*
|
2013-07-02 |
2015-12-23 |
扬州大学 |
取代吡咯烷-2-酮的新合成方法
|
|
JP6453632B2
(ja)
*
|
2013-12-05 |
2019-01-16 |
株式会社日本触媒 |
環状アミドアクリレート含有組成物およびその製造方法
|
|
JP6465634B2
(ja)
*
|
2013-12-05 |
2019-02-06 |
株式会社日本触媒 |
環状アミド基含有重合体
|
|
AU2014368961B2
(en)
|
2013-12-20 |
2019-10-17 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
|
IL279202B2
(en)
|
2014-01-21 |
2023-09-01 |
Janssen Pharmaceutica Nv |
Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
|
|
US10537573B2
(en)
|
2014-01-21 |
2020-01-21 |
Janssen Pharmaceutica Nv |
Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
|
|
CN104098497B
(zh)
*
|
2014-06-17 |
2016-04-13 |
王庚禹 |
一种新的酰胺类化合物
|
|
WO2016075082A1
(en)
|
2014-11-10 |
2016-05-19 |
Sandoz Ag |
Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam
|
|
WO2016131947A1
(en)
|
2015-02-20 |
2016-08-25 |
Ucb Biopharma Sprl |
Combination treatment
|
|
CN106365986B
(zh)
*
|
2015-07-21 |
2019-01-08 |
苏州鹏旭医药科技有限公司 |
化合物及其制备方法和在合成布瓦西坦中的用途
|
|
HRP20240027T1
(hr)
|
2015-05-25 |
2024-04-26 |
Suzhou Pengxu Pharmatech Co., Ltd. |
Postupci za proizvodnju brivaracetama
|
|
CN106279074B
(zh)
*
|
2015-05-25 |
2018-06-26 |
苏州鹏旭医药科技有限公司 |
一种化合物及其制备方法和在合成布瓦西坦中的用途
|
|
DK3310800T3
(da)
|
2015-06-19 |
2022-02-28 |
Centurion Biopharma Corp |
Leveringssystem til styret lægemiddelfrigivelse
|
|
EP3310785B1
(en)
|
2015-06-19 |
2024-11-20 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
|
WO2017076737A1
(en)
|
2015-11-03 |
2017-05-11 |
Ucb Biopharma Sprl |
Continuous process for preparing brivaracetam
|
|
HRP20211518T1
(hr)
|
2015-11-03 |
2021-12-24 |
UCB Biopharma SRL |
Postupak priprave brivaracetama
|
|
CN106748748B
(zh)
*
|
2015-11-10 |
2021-08-24 |
成都国为生物医药有限公司 |
一种布瓦西坦的制备方法及其中间体
|
|
CN105646319B
(zh)
*
|
2015-12-30 |
2018-05-18 |
佛山市隆信医药科技有限公司 |
一种布瓦西坦的制备方法
|
|
CN109069480A
(zh)
|
2015-12-30 |
2018-12-21 |
阿达玛斯医药公司 |
用于治疗与癫痫相关的病症的方法和组合物
|
|
US20210220331A1
(en)
|
2016-05-03 |
2021-07-22 |
The Regents Of The University Of California |
Inhibitors of ires-mediated protein synthesis
|
|
RU2629117C1
(ru)
*
|
2016-06-14 |
2017-08-24 |
Сизов Владимир Владимирович |
Способ получения 4-замещенного 2-[2-оксо-1-пирролидинил] ацетамида
|
|
CN107513031B
(zh)
*
|
2016-06-16 |
2022-08-02 |
上海医药集团股份有限公司 |
一种2-氧代-1-吡咯烷手性衍生物的制备方法
|
|
US20180170941A1
(en)
|
2016-12-19 |
2018-06-21 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
|
US11505555B2
(en)
|
2016-12-19 |
2022-11-22 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
|
AU2018210393A1
(en)
|
2017-01-20 |
2019-07-25 |
The Regents Of The University Of California |
Inhibitors of the N-terminal domain of the androgen receptor
|
|
WO2018141276A1
(zh)
*
|
2017-02-05 |
2018-08-09 |
苏州鹏旭医药科技有限公司 |
布瓦西坦中间体的晶型a及其制备方法和布瓦西坦的晶型c及其制备方法
|
|
CN106866483A
(zh)
*
|
2017-02-05 |
2017-06-20 |
苏州鹏旭医药科技有限公司 |
布瓦西坦的晶型c及其制备方法
|
|
CN108503610B
(zh)
|
2017-02-24 |
2019-09-13 |
北京艾百诺医药股份有限公司 |
一种光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的制备方法
|
|
CN108658831B
(zh)
*
|
2017-03-30 |
2021-11-05 |
江苏豪森药业集团有限公司 |
2-氧代-1-吡咯烷衍生物或其盐的制备方法
|
|
CN118271233A
(zh)
|
2017-04-24 |
2024-07-02 |
特沙诺有限公司 |
尼拉帕利的制造方法
|
|
KR20250151619A
(ko)
|
2017-06-30 |
2025-10-21 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
모발 성장을 조절하기 위한 조성물 및 방법
|
|
JP2020536855A
(ja)
|
2017-09-26 |
2020-12-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
がんを治療するための組成物及び方法
|
|
CN107721896A
(zh)
*
|
2017-10-19 |
2018-02-23 |
丽珠集团新北江制药股份有限公司 |
一种布瓦西坦的中间体的制备方法
|
|
CN107793342A
(zh)
*
|
2017-10-19 |
2018-03-13 |
丽珠集团新北江制药股份有限公司 |
一种布瓦西坦的制备方法
|
|
PT3717503T
(pt)
|
2017-11-30 |
2024-01-16 |
Ladrx Corp |
Profármacos de ligação a albumina de derivados de auristatina e
|
|
JP7442821B2
(ja)
|
2017-11-30 |
2024-03-05 |
センチュリオン バイオファーマ コーポレイション |
メイタンシノイド系薬物送達システム
|
|
EP3749640B1
(en)
|
2018-01-30 |
2025-07-16 |
The Regents of the University of California |
Inhibitors of the wnt/beta-catenin pathway
|
|
CN108147988B
(zh)
*
|
2018-02-13 |
2020-10-02 |
扬州奥锐特药业有限公司 |
一种高手性纯度内酰胺化合物的制备方法
|
|
CN108530402B
(zh)
*
|
2018-04-10 |
2020-06-26 |
浙江工业大学 |
一种(R)-3-丙基-γ-丁内酯的制备方法
|
|
EP3566760A1
(en)
*
|
2018-05-07 |
2019-11-13 |
Universite Libre De Bruxelles |
Method for nucleating crystals from a solution in a capillary tube
|
|
ES2947618T3
(es)
|
2018-05-08 |
2023-08-14 |
UCB Biopharma SRL |
Derivados de 1-imidazotiadiazolo-2H-pirrol-5-ona
|
|
MX2020013927A
(es)
|
2018-06-19 |
2021-03-02 |
Agenebio Inc |
Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.
|
|
CN110615744B
(zh)
|
2018-06-20 |
2023-01-06 |
上海朴颐化学科技有限公司 |
一种布瓦西坦中间体及其制备方法
|
|
WO2020006489A1
(en)
|
2018-06-29 |
2020-01-02 |
The Regents Of The University Of California |
New molecular tweezers against neurological disorders and viral infections
|
|
RU2699669C1
(ru)
*
|
2018-07-04 |
2019-09-09 |
Общество С Ограниченной Ответственностью "Валента - Интеллект" |
Новые составы N-карбамоилметил-4-фенил-2-пирролидона
|
|
CA3107750A1
(en)
|
2018-07-27 |
2020-01-30 |
California Institute Of Technology |
Cdk inhibitors and uses thereof
|
|
EP3867223B1
(en)
|
2018-10-17 |
2025-12-10 |
The Regents of the University of California |
Prodrugs of alpha-ketoglutarate, alpha-ketobutyrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, and uses thereof
|
|
EP3699173A1
(en)
|
2018-10-18 |
2020-08-26 |
California Institute of Technology |
Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same
|
|
CA3118026A1
(en)
|
2018-10-31 |
2020-05-07 |
Intocell, Inc. |
Fused heterocyclic benzodiazepine derivatives and uses thereof
|
|
JOP20210082A1
(ar)
|
2018-12-04 |
2023-01-30 |
Metys Pharmaceuticals AG |
تركيبات تآزرية تشتمل على (r)-2-(2-أوكسو بيروليدين-1-يل)بيوتان أميد و(s)-2-(2-أوكسو بيروليدين-1-يل)بيوتان أميد بنسبة غير راسيمية
|
|
WO2020176386A2
(en)
|
2019-02-25 |
2020-09-03 |
The Regents Of The University Of California |
Methods of carbon-carbon bond fragmentation
|
|
CN109932442A
(zh)
*
|
2019-03-04 |
2019-06-25 |
成都美域高制药有限公司 |
一种布瓦西坦异构体的检测方法
|
|
JP7609798B2
(ja)
|
2019-03-25 |
2025-01-07 |
カリフォルニア インスティチュート オブ テクノロジー |
Ｐｒｍｔ５インヒビター及びその使用
|
|
US12187737B2
(en)
|
2019-06-04 |
2025-01-07 |
Hager Biosciences, Llc |
Imidazolo derivatives, compositions and methods as orexin antagonists
|
|
CN110357752A
(zh)
*
|
2019-08-15 |
2019-10-22 |
中国工程物理研究院化工材料研究所 |
一种快速制备均匀包覆含能材料的方法
|
|
RU2732245C1
(ru)
*
|
2019-08-30 |
2020-09-14 |
Ооо "Валента-Интеллект" |
Новые составы n-карбамоилметил-4-фенил-2-пирролидона для лечения и профилактики ожирения
|
|
CN110551050A
(zh)
*
|
2019-09-02 |
2019-12-10 |
南通大学 |
一种2-[3’-(N-Boc-吡咯基)]-苯甲酸的合成方法
|
|
US10781170B1
(en)
|
2019-10-21 |
2020-09-22 |
Divi's Laboratories Ltd. |
Process for preparing Brivaracetam
|
|
US20230100559A1
(en)
|
2020-01-07 |
2023-03-30 |
The Trustees Of Princeton University |
Compositions and Methods for Treatment of Disease by Manipulation of Serine Metabolism
|
|
US20230113944A1
(en)
|
2020-01-10 |
2023-04-13 |
The Regents Of The University Of California |
Compositions and methods for the treatment of neurodegenerative diseases
|
|
US20230174460A1
(en)
|
2020-04-21 |
2023-06-08 |
President And Fellowes Of Harvard College |
Afmt analogs and their use in methods of treating parkinson's disease
|
|
LV15614A
(lv)
|
2020-07-30 |
2022-02-20 |
Latvijas Organiskās Sintēzes Institūts |
2-(2-okso-3-pirolin-1-il)acetamīdi kā pretkrampju līdzekļi
|
|
CA3191164A1
(en)
|
2020-08-10 |
2022-02-17 |
Dana-Farber Cancer Institute, Inc. |
Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
|
|
CA3191163A1
(en)
|
2020-08-10 |
2022-02-17 |
Dana-Farber Cancer Institute, Inc. |
Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
|
|
US20230271918A1
(en)
|
2020-08-10 |
2023-08-31 |
Dana-Farber Cancer Institute, Inc. |
Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
|
|
CA3193554A1
(en)
*
|
2020-10-06 |
2022-04-14 |
D.E. Shaw Research, Llc |
Lactam compounds as kv1.3 potassium shaker channel blockers
|
|
CN116323571A
(zh)
|
2020-10-23 |
2023-06-23 |
丹娜法伯癌症研究院 |
肌酸激酶（ck）的共价抑制剂以及其用于治疗和预防癌症的用途
|
|
WO2022133237A2
(en)
|
2020-12-18 |
2022-06-23 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
|
IL303813A
(en)
|
2020-12-21 |
2023-08-01 |
Univ Cornell |
Peptide-linked drug delivery system
|
|
WO2022150574A1
(en)
|
2021-01-08 |
2022-07-14 |
Cornell University |
Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
|
|
US11400074B1
(en)
|
2021-02-01 |
2022-08-02 |
Divi's Laboratories Ltd. |
Enzymatic process for the preparation of (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam
|
|
US11384050B1
(en)
*
|
2021-02-03 |
2022-07-12 |
Vitaworks Ip, Llc |
Method for preparing levetiracetam and intermediates thereof
|
|
US12559456B2
(en)
|
2021-02-03 |
2026-02-24 |
Suzhou Brighthope Pharma Tech Co., Ltd |
Method for preparing levetiracetam and intermediates thereof
|
|
CN114948953A
(zh)
*
|
2021-06-29 |
2022-08-30 |
四川大学华西医院 |
一种杂原子取代芳香类化合物及其盐的用途
|
|
CN113511994B
(zh)
*
|
2021-08-16 |
2023-03-21 |
江苏八巨药业有限公司 |
一种左乙拉西坦的制备方法
|
|
CN114634437B
(zh)
*
|
2022-03-29 |
2023-05-30 |
武汉氟本氘合新材料科技有限公司 |
一种布瓦西坦的简易制备方法
|
|
US11884623B2
(en)
|
2022-05-23 |
2024-01-30 |
Divi's Laboratories Ltd. |
Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam
|
|
WO2023250157A1
(en)
|
2022-06-24 |
2023-12-28 |
Cornell University |
Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
|
|
JP2025525415A
(ja)
|
2022-07-13 |
2025-08-05 |
アストラゼネカ・アクチエボラーグ |
Ｐｃｓｋ９阻害剤およびその使用方法
|
|
WO2024039886A1
(en)
|
2022-08-19 |
2024-02-22 |
Agenebio, Inc. |
Benzazepine derivatives, compositions, and methods for treating cognitive impairment
|
|
EP4582412A4
(en)
*
|
2022-08-31 |
2026-01-21 |
Univ Korea Res & Bus Found |
CHIRAL GAMMA LACTAM DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND ITS METHOD OF PREPARATION
|
|
WO2024163711A1
(en)
|
2023-02-02 |
2024-08-08 |
Osmoses Inc. |
Norbornyl benzocyclobutene ladder polymer composite membranes for fluid separation
|
|
CN116041240B
(zh)
|
2023-02-17 |
2024-04-09 |
扬州奥锐特药业有限公司 |
布立西坦中间体的不对称催化氢化合成方法
|
|
EP4431086A1
(en)
|
2023-03-16 |
2024-09-18 |
Adalvo Limited |
Pharmaceutical composition comprising (2s)-2-[(4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl]butanamide
|
|
WO2025078883A2
(en)
|
2023-05-06 |
2025-04-17 |
Prepaire Labs Limited |
Organic compound (oxime) to combat chemical warfare agents
|
|
US12528770B2
(en)
|
2023-06-12 |
2026-01-20 |
Suzhou Brighthope Pharmatech Co., Ltd. |
Process for the production of levetiracetam and intermediates thereof
|
|
TW202525266A
(zh)
|
2023-09-18 |
2025-07-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
可電離類脂質組成物及其治療用途
|
|
WO2025072893A1
(en)
|
2023-09-29 |
2025-04-03 |
Battelle Memorial Institute |
Polymer nanoparticle compositions for non-viral gene delivery
|
|
WO2025072751A1
(en)
|
2023-09-29 |
2025-04-03 |
Battelle Memorial Institute |
Polymer nanoparticle compositions for in vivo expression of polypeptides
|
|
WO2025106670A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025231452A1
(en)
|
2024-05-02 |
2025-11-06 |
Martinez Montemayor Michelle |
Ergosterol peroxide derivatives and uses thereof
|
|
WO2026030679A1
(en)
|
2024-08-01 |
2026-02-05 |
Osmoses Inc. |
Hollow fiber polymer membranes for fluid separation
|